Highlight
– Sunitinib, a tyrosine kinase inhibitor, shows a 21.2% partial response rate in treating metastatic pheochromocytomas and paragangliomas (mPPGLs). – Nearly half of patients (48.2%) remain progression-free at 12 months, with median progression-free survival of 11.9 months. – Safety profile includes a 13.2% treatment discontinuation due to adverse events and a high frequency of grade ≥3 adverse events (57.8%). – Evidence quality remains low to very low but supports sunitinib as a relevant option for disease control in mPPGLs.
Study Background and Disease Burden
Specialty calculators
For clinical reference; use professional judgment.
